Trial reportThe Journal of physiology2011
Losartan abolishes oxidative stress induced by intermittent hypoxia in humans.
Trial report in The Journal of physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Daily Exposure to Mild Intermittent Hypoxia Reduces Blood Pressure in Male Patients with Obstructive Sleep Apnea and Hypertension.American journal of respiratory and critical care medicine · 2022Trial
- Cyclooxygenases 1 and 2 differentially regulate blood pressure and cerebrovascular responses to acute and chronic intermittent hypoxia: implications for sleep apnea.Journal of the American Heart Association · 2014Trial
- Acute intermittent hypercapnic hypoxia augments left ventricular contractility.The Journal of physiology · 2026Article
- A Narrative Review on Nitrate-Rich Diets as Adjuncts to Antihypertensive Therapy: Enhancing Treatment Efficacy via Oxidative Stress Modulation.Biomedicines · 2025Review
- Synergistic Effects of Low-Frequency Ultrasound and Therapeutic Agents on Endothelial and Renal Cells: Emphasis on Cell Functionality, Oxidative Stress, and Inflammatory Markers.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Pulmonary Vascular Responses to Chronic Intermittent Hypoxia in a Guinea Pig Model of Obstructive Sleep Apnea.International journal of molecular sciences · 2024Article
- Advancements in the neurocirculatory reflex response to hypoxia.American journal of physiology. Regulatory, integrative and comparative physiology · 2024Review
- Intermittent hypoxia: a call for harmonization in terminology.Journal of applied physiology (Bethesda, Md. : 1985) · 2023Article
- Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Negative relationship between brain-derived neurotrophic factor (BDNF) and attention: A possible elevation in BDNF level among high-altitude migrants.Frontiers in neurology · 2023Article
- Experimental Models to Study End-Organ Morbidity in Sleep Apnea: Lessons Learned and Future Directions.International journal of molecular sciences · 2022Review
- Pathways of Microcirculatory Endothelial Dysfunction in Obstructive Sleep Apnea: A Comprehensive Ex Vivo Evaluation in Human Tissue.American journal of hypertension · 2022Article
- A comprehensive review of respiratory, autonomic and cardiovascular responses to intermittent hypoxia in humans.Experimental neurology · 2021Review
- Angiotensin II-Type I Receptor Antagonism Does Not Influence the Chemoreceptor Reflex or Hypoxia-Induced Central Sleep Apnea in Men.Frontiers in neuroscience · 2020Article
- Could Adjunctive Pharmacology Mitigate Cardiovascular Consequences of Obstructive Sleep Apnea?American journal of respiratory and critical care medicine · 2019Article
- What is the best treatment strategy for obstructive sleep apnoea-related hypertension?Hypertension research : official journal of the Japanese Society of Hypertension · 2018Article
- Regulation, signalling and functions of hormonal peptides in pulmonary vascular remodelling during hypoxia.Endocrine · 2018Review
- Angiotensin Receptor Expression and Vascular Endothelial Dysfunction in Obstructive Sleep Apnea.American journal of hypertension · 2018Article
- Plasma Exosomes and Improvements in Endothelial Function by Angiotensin 2 Type 1 Receptor or Cyclooxygenase 2 Blockade following Intermittent Hypoxia.Frontiers in neurology · 2017Article
- N-Acetylcysteine reduces hyperacute intermittent hypoxia-induced sympathoexcitation in human subjects.Experimental physiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The aim of this study was to assess the role of the type 1 angiotensin II (AT(1)) receptor in the increase of oxidative stress and NO metabolism during a single 6 h exposure to intermittent hypoxia (IH). Nine healthy young men were exposed, while awake, to sham IH, IH with placebo medication, and IH with the AT(1) receptor antagonist, losartan, using a double-blind, placebo-controlled, randomized, crossover study design. In addition to blood pressure, oxidative stress, peroxynitrite activity, uric acid, global antioxidant status and the end-products of NO (NOx) metabolism were measured in plasma before and after 6 h of IH. Oxidative stress and peroxynitrite activity increased and NOx decreased during IH with placebo. In contrast, neither sham IH nor IH with losartan affected these parameters. With respect to each condition, blood pressure had the same profile as oxidative stress. These results demonstrate that blockade of AT(1) receptors prevented the increase in oxidative stress and peroxynitrite activity and the decrease in NO metabolism induced by IH. Finally, this study suggests that the renin-angiotensin system may participate in the overproduction of reactive oxygen species associated with IH by upregulation of the actions of angiotensin II.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.